Alabama Clinical Trials Unit - Administrative Supplement: SARS-CoV-2 Testing

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

  • Research Location

    United States of America, Americas
  • Lead Research Institution

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory


  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details


  • Broad Policy Alignment


  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable


Program Director/Principal Investigator (Last, First, Middle): Overton, Edgar TurnerAbstract:The Alabama CRS is intimately involved in the response to the Alabama COVID-19 epidemic. Our researchteam is currently involved in multiple components of the local response, including COVID-19 testing fordiagnosis, antibody testing for epidemiology and for the development of therapeutic and preventive therapies,contact tracing of COVID-19 patients, outpatient and inpatient management of COVID-19 patients, employeehealth initiatives to prevent COVID-19 among our healthcare workers, expanded testing in the community(particularly to marginalized populations), providing education both within our institution and to the outsidecommunity, as well as leading research initiatives in the state of Alabama. In our efforts to flatten the curve andmitigate COVID-19 disease in our state, we desperately need additional resources, including additional staffing,additional testing capacity for both PCR and antibody testing, and reagents to complete that work. Thissupplement provides our team the very resources needed to achieve these aims.For this proposal, we will augment our ongoing efforts with the following projects. We are adding two nursepractitioners to our team. With their level of experience, they will assist with several aspects of the proposal,including expanded testing in community and for research studies, identifying acute and convalescent patientsto perform both PCR testing and blood draws to facilitate an understanding of viral kinetics, as well as theevolution of host responses in COVID-19 patients. The data and virologic and serologic samples will provide keyinsight in to the distribution and natural history of COVID-19 among both rural and urban settings in Alabama.Additionally, these data will inform a greater understanding of the host-viral interaction and host factors thatcontribute to severity of disease. Currently, we have very little testing being performed outside of the urbancenters and have very little understanding of our rural areas.Dr. Heath has partnered with Dr. Barbara Van Der Pol and her molecular diagnostics lab to increase testingcapacity for our institution and Alabama, at large. Their laboratory team have the capacity to perform anadditional 200 PCR tests per day. We will leverage this laboratory infrastructure to enhance testing forpopulations that are unable to come to testing sites in our urban centers. In addition, Dr. Heath's lab hasexpanded capacity to develop sensitive, specific antibody testing approaches to characterize the natural historyof disease, and more importantly to identify donors for life-saving plasma donation. These initiatives will alsoinform the search for surrogates of protection among convalescent COVID-19 patients and the search forvaccine-elicited immunity, as well as monoclonal antibodies.OMB No. 0925-0001/0002 (Rev. 03/2020 Approved Through 02/28/2023) Page Continuation Format Page